BIOCRYST PHARMACEUTICALS, INC. (BCRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 208.85M USD | Liabilities, Current |
| Cash and equivalents | 154.97M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 110.76M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.06M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $208.85M | $154.97M | (m) | $110.76M | $6.06M | (m) |
| 2026-03-31 | (m) | $195.39M | $171.59M | (m) | $109.27M | $5.99M | (m) |
| 2025-12-31 | (m) | $196.07M | $89.74M | (m) | $106.82M | $5.40M | (m) |
| 2025-09-30 | (m) | $190.24M | $84.08M | (m) | $91.33M | $5.23M | (m) |
| 2025-06-30 | (m) | $177.16M | $88.03M | (m) | $91.18M | $5.04M | (m) |
| 2025-03-31 | (m) | $139.85M | $105.19M | (m) | $93.39M | $6.87M | (m) |
| 2024-12-31 | $399.92M | $160.38M | $104.71M | $216.14M | $79.07M | $31.27M | 2.49× |
| 2024-09-30 | $402.47M | $153.57M | $96.84M | $233.17M | $72.46M | $7.56M | 2.62× |
| 2024-06-30 | $340.79M | $129.06M | $78.41M | $193.62M | $68.76M | $4.45M | 2.64× |
| 2024-03-31 | $397.14M | $119.92M | $84.33M | $252.22M | $60.59M | $29.78M | 3.31× |
| 2023-12-31 | $445.94M | $149.99M | $110.64M | $278.34M | $56.95M | $28.68M | 2.97× |
| 2023-09-30 | $451.24M | $90.76M | $150.91M | $246.69M | $53.65M | $29.63M | 4.97× |
| 2023-06-30 | $468.34M | $93.50M | $146.22M | $264.45M | $57.67M | $27.03M | 5.01× |
| 2023-03-31 | $446.80M | $85.16M | $155.14M | $243.02M | $48.64M | $27.47M | 5.25× |
| 2022-12-31 | $474.91M | $105.51M | $304.77M | $119.54M | $50.60M | $27.53M | 4.50× |
| 2022-09-30 | $469.47M | $81.64M | $246.90M | $179.96M | $42.61M | $27.02M | 5.75× |
| 2022-06-30 | $458.97M | $95.39M | $272.57M | $144.91M | $41.49M | $23.38M | 4.81× |
| 2022-03-31 | $479.88M | $81.02M | $395.50M | $47.96M | $36.41M | $16.14M | 5.92× |
| 2021-12-31 | $537.01M | $103.72M | $504.39M | $3.21M | $29.41M | $15.79M | 5.18× |
| 2021-09-30 | $225.81M | $133.61M | $199.60M | $0.00 | $26.21M | $13.66M | 1.69× |
| 2021-06-30 | $246.05M | $115.60M | $210.31M | $8.11M | $27.62M | $9.85M | 2.13× |
| 2021-03-31 | $258.74M | $101.20M | $226.90M | $13.45M | $18.39M | $5.11M | 2.56× |
| 2020-12-31 | $309.01M | $105.65M | $272.13M | $28.24M | $8.65M | $7.04M | 2.92× |
| 2020-09-30 | $148.74M | $111.78M | $96.49M | $46.83M | $5.42M | $6.24M | 1.33× |
| 2020-06-30 | $193.40M | $102.65M | $173.47M | $15.94M | $4.00M | $5.23M | 1.88× |
| 2020-03-31 | $118.70M | $92.70M | $101.87M | $11.19M | $5.64M | (m) | 1.28× |
| 2019-12-31 | $158.37M | $92.33M | $114.17M | $22.05M | $22.15M | (m) | 1.72× |
| 2019-09-30 | $72.03M | $82.17M | $29.90M | $38.53M | $3.60M | $1.78M | 0.88× |
| 2019-06-30 | $95.75M | $71.95M | $30.76M | $61.39M | $3.60M | $1.00M | 1.33× |
| 2019-03-31 | $112.56M | $66.33M | $34.80M | $72.75M | $5.00M | $600.00K | 1.70× |
| 2018-12-31 | $108.76M | $69.48M | $26.73M | $77.74M | $4.29M | $1.65M | 1.57× |
| 2018-09-30 | $123.72M | $64.36M | $52.58M | $67.74M | $3.39M | $821.00K | 1.92× |
| 2018-06-30 | $83.08M | $74.17M | $27.10M | $53.64M | $2.34M | $221.00K | 1.12× |
| 2018-03-31 | $97.00M | $75.34M | $43.77M | $47.54M | $5.69M | $7.00K | 1.29× |
| 2017-12-31 | $120.51M | $74.84M | $50.28M | $64.11M | $6.12M | (m) | 1.61× |
| 2017-09-30 | $170.61M | $69.24M | $117.78M | $43.85M | $8.98M | (m) | 2.46× |
| 2017-06-30 | $84.00M | $58.94M | $39.70M | $40.98M | $3.33M | $1.30M | 1.43× |
| 2017-03-31 | $108.25M | $58.56M | $75.16M | $23.52M | $9.56M | $655.00K | 1.85× |
| 2016-12-31 | $63.42M | $54.36M | $22.10M | $32.55M | $8.77M | $500.00K | 1.17× |
| 2016-09-30 | $58.79M | $51.52M | $35.39M | $17.43M | $5.97M | $2.23M | 1.14× |
| 2016-06-30 | $37.97M | $56.19M | $8.66M | $27.08M | $2.23M | $1.95M | 0.68× |
| 2016-03-31 | (m) | $63.07M | $12.90M | $22.91M | (m) | $1.95M | (m) |
| 2015-12-31 | (m) | $64.45M | $28.90M | $22.66M | (m) | $1.61M | (m) |
| 2015-09-30 | (m) | $64.44M | $46.63M | $23.70M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $63.77M | $76.78M | $17.58M | (m) | $1.31M | (m) |
| 2015-03-31 | (m) | $61.86M | $48.37M | $19.16M | (m) | $1.21M | (m) |
| 2014-12-31 | (m) | $57.69M | $54.54M | $18.23M | (m) | $683.00K | (m) |
| 2014-09-30 | (m) | $49.82M | $121.16M | $5.98M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $44.94M | $121.52M | $10.59M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $13.69M | $13.58M | $17.81M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $15.26M | $21.16M | $16.89M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $13.18M | $26.05M | $16.54M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $11.96M | $19.77M | $9.36M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $11.32M | $14.80M | $13.46M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $17.22M | $20.89M | $14.71M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $12.56M | $23.96M | $17.06M | (m) | $263.00K | (m) |
| 2012-06-30 | (m) | $19.11M | $21.92M | $12.96M | (m) | $263.00K | (m) |
| 2012-03-31 | (m) | $16.16M | $27.66M | (m) | (m) | $263.00K | (m) |
| 2011-12-31 | (m) | $26.30M | $16.44M | (m) | (m) | $263.00K | (m) |
| 2011-09-30 | (m) | $19.33M | $22.44M | $21.56M | (m) | $898.00K | (m) |
| 2011-06-30 | (m) | $21.96M | $17.01M | $40.58M | (m) | $898.00K | (m) |
| 2011-03-31 | (m) | (m) | $31.34M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $27.82M | $13.62M | $40.32M | (m) | $898.00K | (m) |
| 2010-09-30 | (m) | (m) | $11.17M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $14.02M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $41.13M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $22.34M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |